1210419-33-2

Upstream product

• 1210419-26-3 methyl 6-bromo-5-fluoropyridine-2-carboxylate 
• 1052714-46-1 6-bromo-5-fluoro-pyridine-2-carboxylic acid 
• 374633-36-0 2-bromo-3-fluoro-6-methylpyridine 
• 1210419-27-4 methyl 6-(3-(benzyloxy)-2,6-difluorophenyl)-5-fluoropicolinate 

Downstream Products

• 1210419-44-5 methyl 6-(2,6-difluoro-3-(trifluoromethyl-sulfonyloxy)phenyl)-5-fluoropicolinate 
• 1395281-25-0 methyl 6-(3-(2-(tert-butyldimethylsilyloxy)ethoxy)-2,6-difluorophenyl)-5-fluoropicolinate 
• 1395986-13-6 6-(3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2,6-difluorophenyl)-5-fluoropicolinic acid 
• 1395986-06-7 methyl 6-(3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2,6-difluorophenyl)-5-fluoropicolinate 
• 1395281-28-3 6-(3-(2-(tert-butyldimethylsilyloxy)ethoxy)-2,6-difluorophenyl)-5-fluoropicolinic acid 
• 1395281-22-7 6-(2,6-difluoro-3-(2-methoxyethoxy)phenyl)-5-fluoropicolinic acid 
• 1395281-19-2 methyl 6-(2,6-difluoro-3-(2-methoxyethoxy)phenyl)-5-fluoropicolinate 

Relevant academic research and scientific papers

TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

NOVEL KINASE INHIBITORS

The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.

Kinase inhibitors and methods of their use

New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.